Skip to content
Torsemide
Soaanz (torsemide) is a small molecule pharmaceutical. Torsemide was first approved as Demadex on 1993-08-23. It is used to treat ascites, chronic kidney failure, edema, heart failure, and hypertension amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Soaanz (generic drugs available since 2002-05-14, discontinued: Demadex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Torsemide
Tradename
Company
Number
Date
Products
SOAANZSarfez PharmaceuticalsN-213218 RX2021-06-14
3 products, RLD
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
demadexNew Drug Application2009-08-04
soaanzNew Drug Application2021-12-28
torsemideANDA2023-06-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ascitesHP_0001541D001201R18
chronic kidney failureEFO_0003884D007676N18.6
edema—D004487R60.9
heart failureEFO_0003144D006333I50
hypertensionEFO_0000537D006973I10
liver cirrhosisEFO_0001422D008103K74.0
nephrotic syndromeEFO_0004255D009404N04
pulmonary edemaEFO_1001134D011654J81
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Torsemide, Soaanz, Sarfe Pharms
101549632033-10-06DP
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03C: High-ceiling diuretics
— C03CA: Sulfonamides, high-ceiling diuretics, plain
— C03CA04: Torasemide
HCPCS
Code
Description
J3265
Injection, torsemide, 10 mg/ml
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CystinuriaD003555E72.01—1—1—2
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chemical and drug induced liver injuryD056486—1———1
Subarachnoid hemorrhageD013345EFO_0000713I60—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTORSEMIDE
INNtorasemide
Description
Torasemide is an N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure. It has a role as a loop diuretic and an antihypertensive agent. It is a N-sulfonylurea, an aminopyridine and a secondary amino compound. It is functionally related to a 4-aminopyridine.
Classification
Small molecule
Drug classdiuretics (furosemide type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1
Identifiers
PDB—
CAS-ID56211-40-6
RxCUI38413
ChEMBL IDCHEMBL1148
ChEBI ID9637
PubChem CID41781
DrugBankDB00214
UNII IDW31X2H97FB (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,947 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,508 adverse events reported
View more details